Judy Knudson PA-C speaks to ecancer at the online ONS 2020 meeting about the use of PARP inhibitors in oncology.
She explains the perspective from a palliative care nurse, which normally only sees the patients for whom PARP inhibitors did not work.
She does explain the benefits to the patient that arise from oral treatments, but sometimes these benefits come at a financial or toxic cost.
She is overall extremely excited about the prospects of these medicines.
Ms Knudson then explains the impact of the COVID-19 pandemic on palliative care including telecommunication, video calling, and healthcare professional self-care.
This programme has been supported by an unrestricted educational grant from Pfizer.